Skip to Content

Seroquel XR Approval History

Seroquel XR (quetiapine) is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia, bipolar disorder and as an adjunctive treatment to antidepressants in adults with Major Depressive Disorder.

Development History and FDA Approval Process for Seroquel XR

Dec  4, 2009Approval FDA Approves Seroquel XR For Add-On Treatment of Major Depressive Disorder
Oct 10, 2008Approval FDA Approves AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US
Nov 16, 2007Approval Seroquel XR Receives Approval From FDA for Maintenance Treatment ofSchizophrenia
May 18, 2007Approval FDA Approves Astrazeneca's Once-Daily Seroquel XR Extended-ReleaseTablets for the Treatment of Schizophrenia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.